Conditioning techniques and ischemic reperfusion injury in relation to on-pump cardiac surgery.
OBJECTIVE
The objective was to investigate the potential protective effects of two conditioning methods, on myocardial ischemic and reperfusion injury in relation to cardiac surgery.


METHODS
Totally 68 patients were randomly assigned to either a control group (n = 23), a remote ischemic preconditioning (RIPC) group (n = 23) or a glucagon-like peptide-1 (GLP-1) analogue group (n = 22). The RIPC protocol consisted of three cycles of upper limb ischemia. The GLP-1 analogue protocol consisted of intravenous infusion with exenatide. The primary endpoint was postoperative cardiac enzyme release. The other secondary endpoints were metabolic parameters related to myocardial ischemia, measured using microdialysis technique, as well as other operative- and postoperative data.


RESULTS
Postoperative cardiac enzyme release indicated a possible beneficial effect of the interventions, but the difference did not reach statistical significance. RIPC showed a trend toward lower levels (p = 0.07). We managed to establish a functional myocardial microdialysis model, but we were unable to demonstrate clear protective effects.


CONCLUSIONS
We were in this prospective randomized proof-of-concept trial, unable to show distinct protective effects of the studied conditioning methods. However, this trial can hopefully contribute to generate a productive discussion concerning limitations and future use of cardiac conditioning as well as microdialysis technique.
Department of Cardiovascular and Thoracic Surgery , Rigshospitalet, Copenhagen , Denmark.
Fredrik Eric Olof
FE
Holmberg
Konstantin Alex
KA
Ottas
Charlotte
C
Andreasen
Mario J
MJ
Perko
Christian H
CH
Møller
Thomas
T
Engstrøm
Daniel A
DA
Steinbrüchel
D000368:Aged; D015415:Biomarkers / Q000097:blood; D006348:Cardiac Surgical Procedures / Q000009:adverse effects*; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D052279:Creatine Kinase, MB Form / Q000097:blood; D003718:Denmark; D000077270:Exenatide; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D019194:Ischemic Preconditioning / Q000379:methods*; D008297:Male; D017551:Microdialysis; D008875:Middle Aged; D015428:Myocardial Reperfusion Injury / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D010455:Peptides / Q000008:administration & dosage*; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D020107:Troponin T / Q000097:blood; D034941:Upper Extremity / Q000098:blood supply*; D014688:Venoms / Q000008:administration & dosage*
D015415:Biomarkers; D010455:Peptides; D020107:Troponin T; D014688:Venoms; D000077270:Exenatide; D052279:Creatine Kinase, MB Form
glucagon-like peptide 1 analogue; microdialysis; remote ischemic preconditioning; reperfusion injury